Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data-Reference-Cited by-同舟云学术

Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data

Published:2019-05-02 Issue:1 Volume:21 Page:
ISSN:1478-6362
Container-title:Arthritis Research & Therapy
language:en
Short-container-title:Arthritis Res Ther

Author:

Deodhar A.,Mease P. J.,McInnes I. B.,Baraliakos X.,Reich K.,Blauvelt A.,Leonardi C.,Porter B.,Das Gupta A.,Widmer A.,Pricop L.,Fox T.

Publisher

Springer Science and Business Media LLC

Link

http://link.springer.com/content/pdf/10.1186/s13075-019-1882-2.pdf

Reference50 articles.

1. Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells. N Engl J Med. 2009;361(9):888–98.

2. Krstic A, Mojsilovic S, Jovcic G, Bugarski D. The potential of interleukin-17 to mediate hematopoietic response. Immunol Res. 2012;52(1–2):34–41.

3. Patel DD, Lee DM, Kolbinger F, Antoni C. Effect of IL-17A blockade with secukinumab in autoimmune diseases. Ann Rheum Dis. 2013;72(Suppl 2):ii116–23.

4. Blauvelt A, Chiricozzi A. The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis. Clin Rev Allergy Immunol. 2018.

5. Baecklund E, Iliadou A, Askling J, Ekbom A, Backlin C, Granath F, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum. 2006;54(3):692–701.

Cited by 231 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment of psoriasis with biologic and non‐biologic targeted therapies in patients with latent tuberculosis infection or at risk for tuberculosis disease progression: Recommendations from a SPIN‐FRT expert consensus;Journal of the European Academy of Dermatology and Venereology;2024-08-16

2. Psoriasis and psoriatic arthritis following use of dostarlimab for endometrial cancer;BMJ Case Reports;2024-08

3. Four-year real-world experience of secukinumab in a large Italian cohort of axial spondyloarthritis;Frontiers in Immunology;2024-07-15

4. Evaluation of serial QuantiFERON‐TB Gold in tube test results and tuberculosis infection status in patients with psoriasis receiving anti‐IL‐17 treatment (secukinumab and ixekizumab): Real‐world data from a tuberculosis‐endemic country;Australasian Journal of Dermatology;2024-07

5. Pharmacokinetics, Safety, and Immunogenicity of Intravenous and Subcutaneous Single-Dose QX002N Injection in Healthy Subjects: A Randomized, Open, Parallel, Single-Center, Phase I Study;Rheumatology and Therapy;2024-06-09